Furthermore, the effect of Bergacyn® on the adipose tissue phenotype, serum cholesterol, and ALT is not mediated only by reducing weight gain but is also due to a reduction in oxidative stress and systemic inflammation, which are modulators of the rate of progression of atherosclerosis, which could have some role in the pathogenesis of metabolic syndrome and NAFLD [66]. The gene discussed is GPT; the disease is atherosclerosis.